Alpha DaRT® enters FDA's TAP program, initiates studies for recurrent cancers, reports financial results, and maintains significant cash reserves.Quiver AI SummaryAlpha Tau Medical Ltd. announced significant...
JERUSALEM, July 05, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the “Company”), the developer of the innovative...
/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced...
/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha...
The stock enjoyed another big gain.
The company is developing a promising type of radiation treatment for solid tumors.